Disc Medicine (IRON) Receives a Buy from LifeSci Capital
I'm LongbridgeAI, I can summarize articles.
LifeSci Capital analyst Rami Katkhuda has maintained a Buy rating on Disc Medicine (NASDAQ: IRON) with a price target of $100.00. Katkhuda, a 5-star analyst, has an average return of 31.8% and a 55.75% success rate. Additionally, Truist Financial's Danielle Brill also issued a Buy rating on Disc Medicine on February 17, while TipRanks reiterated a Hold rating on February 4.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments